Brief: Inhibikase Therapeutics Reports Q3 Loss Per Share Of $0.18
15/11/2021 23:07
Nov 15 (Reuters) - Inhibikase Therapeutics Inc IKT.O :
* INHIBIKASE THERAPEUTICS REPORTS THIRD QUARTER 2021
FINANCIAL
RESULTS AND HIGHLIGHTS RECENT PERIOD ACTIVITY
* Q3 LOSS PER SHARE $0.18
Source text for Eikon: ID:nPnCVpYHa
Further company coverage: IKT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inhibikase Therapeutics
See all newsBrief: Inhibikase Therapeutics Appoints Scott Wasserman To Board Of Directors
Inhibikase Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Inhibikase Q2 net loss widens on higher R&D, SG&A costs
Inhibikase Therapeutics, Inc. expected to post a loss of 11 cents a share - Earnings Preview
Brief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share